Magenta therapeutics presents positive mgta-117 clinical data at the american society of hematology (ash) annual meeting and provides program updates

– mgta-117 preliminary clinical results from 15 patients across three dose-escalation cohorts of the ongoing phase 1/2 clinical trial shows single-agent activity with no dose-limiting toxicities; transition to patients with transplant-eligible aml/mds expected in h1 2023 pending regulatory alignment –
DNTH Ratings Summary
DNTH Quant Ranking